Valuation: argenx SE

Market Cap 62.99B 54.41B 51.19B 46.53B 87.51B 6,036B 88.79B 600B 235B 3,019B 237B 231B 10,055B P/E 2026 *
36.2x
P/E 2027 * 29.1x
Enterprise Value 57.58B 49.73B 46.79B 42.53B 79.99B 5,517B 81.16B 549B 215B 2,759B 216B 211B 9,191B EV / Sales 2026 *
9.26x
EV / Sales 2027 * 7.2x
Free-Float
99.98%
Yield 2026 *
0.04%
Yield 2027 * 0.08%

Last Transcript: argenx SE

1 day+1.73%
1 week+16.15%
Current month+16.78%
1 month+15.69%
3 months+28.77%
6 months+21.78%
Current year+21.37%
1 week 723.4
Extreme 723.4
870
1 month 717.4
Extreme 717.4
870
Current year 568.4
Extreme 568.4
870
1 year 558.6
Extreme 558.6
870
3 years 271
Extreme 271
870
5 years 224.1
Extreme 224.1
870
10 years 12.5
Extreme 12.5
870
Manager TitleAgeSince
Chief Executive Officer 47 2026-05-05
Director of Finance/CFO 56 2021-05-31
Chief Tech/Sci/R&D Officer - 2014-12-31
Director TitleAgeSince
Chairman 54 2026-05-05
Director/Board Member 76 2015-05-12
Director/Board Member 65 2016-04-27
Date Insider Type Main position Quantity % Market Cap.
11/23/25 Sell

Chief Executive Officer

2,000 0.0032%
11/23/25 Sell

Director

4,680 0.0076%
11/23/25 Fiscal year

Director

4,680 0.0076%
Change 5-day change 1-year change 3-year change Capi.($)
+1.73%+16.15%+51.73%+93.89% 62.99B
+0.17%+4.35%+72.39%+114.97% 73.45B
+0.11%-3.10%+0.94%+491.16% 28.05B
-1.69%+4.51%+60.38%+20.00% 25.42B
+1.26%-0.05%-17.59%-15.96% 23.3B
0.00%+5.57%+39.57%-14.30% 19.45B
-0.71%-4.11%+243.99%+423.83% 18.16B
-3.59%-1.04%+14.69%+515.29% 16.53B
+1.53%+3.49%+40.68%+151.75% 13.16B
-0.90%-1.50%+341.49%+211.04% 12.42B
Average -0.21%+2.19%+84.82%+199.17% 29.29B
Weighted average by Cap. +0.16%+4.69%+68.09%+166.69%

Financials

2026 *2027 *
Net sales 6.22B 5.37B 5.05B 4.59B 8.64B 596B 8.76B 59.27B 23.23B 298B 23.34B 22.84B 992B 7.68B 6.63B 6.24B 5.67B 10.67B 736B 10.83B 73.22B 28.69B 368B 28.84B 28.21B 1,226B
Net income 1.87B 1.62B 1.52B 1.38B 2.6B 179B 2.64B 17.83B 6.99B 89.65B 7.02B 6.87B 299B 2.49B 2.15B 2.03B 1.84B 3.46B 239B 3.51B 23.75B 9.31B 119B 9.36B 9.15B 398B
Net Debt -5.41B -4.68B -4.4B -4B -7.52B -519B -7.63B -51.6B -20.22B -259B -20.33B -19.88B -864B -7.71B -6.66B -6.26B -5.69B -10.71B -739B -10.87B -73.49B -28.8B -369B -28.94B -28.32B -1,230B
Logo argenx SE
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.
Employees
1,863
Date Price Change Volume
26-08-18 €870.00 +1.73% 116,076
26-08-17 €855.20 +17.12% 158,662
26-08-14 €730.20 -3.21% 56,271
26-08-13 €754.40 -0.87% 50,123
26-08-12 €761.00 +1.60% 50,734
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1,007.29USD
Average target price
1,091.11USD
Spread / Average Target
+8.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARGX Stock